Insulet Co. (PODD) Expected to Post Earnings of -$0.13 Per Share

Wall Street analysts expect Insulet Co. (NASDAQ:PODD) to post earnings per share of ($0.13) for the current quarter, according to Zacks. Ten analysts have issued estimates for Insulet’s earnings, with the highest EPS estimate coming in at ($0.07) and the lowest estimate coming in at ($0.18). Insulet also posted earnings of ($0.13) per share in the same quarter last year. The firm is expected to announce its next earnings report on Thursday, August 2nd.

According to Zacks, analysts expect that Insulet will report full-year earnings of ($0.18) per share for the current financial year, with EPS estimates ranging from ($0.28) to ($0.09). For the next financial year, analysts expect that the company will post earnings of $0.33 per share, with EPS estimates ranging from $0.05 to $0.51. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Insulet.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, May 3rd. The medical instruments supplier reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.08. The business had revenue of $123.60 million for the quarter, compared to analyst estimates of $121.76 million. Insulet had a negative return on equity of 20.02% and a negative net margin of 4.82%. The company’s quarterly revenue was up 21.5% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.17) EPS.

PODD has been the topic of a number of research analyst reports. BMO Capital Markets initiated coverage on Insulet in a research note on Monday, March 5th. They issued an “outperform” rating and a $90.00 target price on the stock. BidaskClub upgraded Insulet from a “hold” rating to a “buy” rating in a research note on Friday, March 9th. Zacks Investment Research upgraded Insulet from a “sell” rating to a “hold” rating in a research note on Tuesday, March 13th. ValuEngine upgraded Insulet from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. Finally, Guggenheim initiated coverage on Insulet in a research note on Tuesday, April 3rd. They issued a “buy” rating and a $105.00 target price on the stock. Five investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Insulet has a consensus rating of “Buy” and an average price target of $90.18.

In related news, SVP Michael P. Spears sold 8,114 shares of the firm’s stock in a transaction that occurred on Tuesday, May 15th. The stock was sold at an average price of $86.64, for a total transaction of $702,996.96. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director David A. Lemoine sold 1,084 shares of the firm’s stock in a transaction that occurred on Tuesday, May 1st. The stock was sold at an average price of $84.93, for a total value of $92,064.12. The disclosure for this sale can be found here. Insiders have sold a total of 42,277 shares of company stock worth $3,875,186 over the last quarter. Corporate insiders own 3.60% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Frontier Capital Management Co. LLC grew its position in Insulet by 7.1% during the 1st quarter. Frontier Capital Management Co. LLC now owns 2,245,988 shares of the medical instruments supplier’s stock worth $194,682,000 after acquiring an additional 149,857 shares during the last quarter. Fred Alger Management Inc. grew its position in Insulet by 32.5% during the 4th quarter. Fred Alger Management Inc. now owns 1,808,616 shares of the medical instruments supplier’s stock worth $124,795,000 after acquiring an additional 443,970 shares during the last quarter. Lord Abbett & CO. LLC grew its position in Insulet by 2.9% during the 1st quarter. Lord Abbett & CO. LLC now owns 1,208,861 shares of the medical instruments supplier’s stock worth $104,784,000 after acquiring an additional 34,025 shares during the last quarter. Millennium Management LLC grew its position in Insulet by 154.1% during the 4th quarter. Millennium Management LLC now owns 941,567 shares of the medical instruments supplier’s stock worth $64,968,000 after acquiring an additional 571,082 shares during the last quarter. Finally, Renaissance Technologies LLC grew its position in Insulet by 328.2% during the 4th quarter. Renaissance Technologies LLC now owns 661,200 shares of the medical instruments supplier’s stock worth $45,623,000 after acquiring an additional 506,800 shares during the last quarter.

Shares of NASDAQ PODD opened at $85.70 on Thursday. The stock has a market capitalization of $5.17 billion, a price-to-earnings ratio of -186.30 and a beta of 1.37. The company has a debt-to-equity ratio of 3.34, a quick ratio of 5.16 and a current ratio of 5.48. Insulet has a twelve month low of $48.82 and a twelve month high of $102.89.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.

Get a free copy of the Zacks research report on Insulet (PODD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply